By securing the rights to a Phase II dissolvable implant for glaucoma and diabetic retinopathy, targeting the underlying vascular causes of vision loss, Bayer is positioning itself at the forefront of long-acting ocular drug delivery.

The acquisition is expected to create a global powerhouse in women’s health, biosimilars and branded generics with operations in 150 countries, and is set to close in early 2027 pending approvals.

With this definitive acquisition agreement, the CDMO will expand its presence on the global market with its first European location and will enable greater customer support.

The companies have entered into the evaluation agreement to investigate whether circVec circular RNA technology can be delivered to T cells using Acuitas’ targeted lipid nanoparticles.

Aptar Pharma has entered into a technical collaboration with COVIRIX Medical to evaluate its handheld dry powder inhaler device with broad‑spectrum antiviral compounds for high‑risk respiratory viruses.

San Diego-based Trenchant BioSystems has partnered with engineering firm Invetech to develop a fully automated manufacturing platform it claims could cut production costs by up to 80%.

Under this new arrangement, the companies will work together to further develop Indomo’s DT-001 candidate, which will be combined with the ClearPen device to allow self-treatment of inflammatory acne lesions.

In efforts to streamline its portfolio and prioritize core capabilities, the company has agreed two separate transactions to divest its CDMO and Cell Solutions as well as select European Discovery Services sites.

The companies will integrate their strengths from early-stage development and commercial-scale GMP API manufacturing to offer clients an end-to-end API solution.

Kidswell Bio and Treehill Partners have joined forces to create a new company aimed at accelerating the clinical development of a novel SHED stem cell therapy showing early efficacy signals for pediatric cerebral palsy (CP).

With a looming patent cliff, continuing geopolitical pressures, and regionalized supply chains, there is a need for new creative deal structures and alternative financing to ensure successful M&A momentum.

A manufacturing collaboration between ten23 health and BD will support the commercialization of a wearable injector platform that offers a ready-to-use option for subcutaneous administration of high-dose biologics.

The agreement will allow AbbVie to develop, manufacture, and commercialize RemeGen’s novel PD-1/VEGF bispecific antibody in combination with its ADCs across multiple solid tumors.

Insilico Medicine has entered a multi‑year R&D collaboration with Servier to discover and develop novel AI‑designed oncology therapies. The deal will combine Insilico’s Pharma.AI platform with Servier’s global oncology development and commercialization capabilities.

Sweden’s Nanexa has entered a licensing and option deal with Moderna, granting access to its PharmaShell drug delivery platform to develop long-acting versions of Moderna’s mRNA-based therapies.

To strengthen its European presence and enhance high-impact event experiences for life science clients worldwide, ITA Group has acquired C2events, a UK-based event management agency specializing in healthcare and pharmaceutical conferences.

A collaboration between Rentschler Biopharma and Coriolis Pharma has been formed that will draw upon complementary scientific and technical expertise to provide end-to-end solutions for the biopharmaceutical value chain.

A strategic research collaboration has been announced by Biogen and Dayra Therapeutics aimed at the discovery and development of oral macrocyclic peptides that could disrupt traditional antibody-based treatments.

In collaboration with A.forall and IMGA, Nanoform has formed a new subsidiary aimed at outlicensing Nanoencorafenib as an attractive patient-centric lifecycle management opportunity or value-added generic medicine opportunity.

The companies have entered into a definitive agreement for the acquisition, which includes an investigational immunotherapy preclinical candidate and a proprietary RNA modular platform.